<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089084</url>
  </required_header>
  <id_info>
    <org_study_id>AROAPOC3-3001</org_study_id>
    <nct_id>NCT05089084</nct_id>
  </id_info>
  <brief_title>Study of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome (FCS)</brief_title>
  <official_title>A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrowhead Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arrowhead Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose or AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 in adult&#xD;
      participants with familial chylomicronemia syndrome (FCS). Participants who have met all&#xD;
      protocol eligibility criteria will be randomized to receive 4 total doses of ARO-APOC3 or&#xD;
      matching placebo administered subcutaneously.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change from Baseline in Fasting Triglycerides (TG) at Month 10</measure>
    <time_frame>Baseline, Month 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Apolipoprotein C-III (APOC3) at Month 10</measure>
    <time_frame>Baseline, Month 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Month 10</measure>
    <time_frame>Baseline, Month 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Month 10</measure>
    <time_frame>Baseline, Month 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting TG at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting APOC3 at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting Non-HDL-C at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting HDL-C at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Achieving TG of &lt; 500 mg/dL at Month 10</measure>
    <time_frame>Month 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Achieving TG of &lt; 500 mg/dL at Month 12</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting TG Over Time</measure>
    <time_frame>Baseline, up through Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting TG Over Time</measure>
    <time_frame>Baseline, up through Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment-Emergent Adverse Events (AEs) and/or Serious Adverse Events (SAEs)</measure>
    <time_frame>From first dose of study drug through Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Positively Adjudicated Events of Acute Pancreatitis</measure>
    <time_frame>From first dose of study drug through Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Familial Chylomicronemia</condition>
  <arm_group>
    <arm_group_label>ARO-APOC3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 doses or ARO-APOC3 by subcutaneous (sc) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>calculated volume to match active treatment by sc injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARO-APOC3</intervention_name>
    <description>ARO-APOC3 injection</description>
    <arm_group_label>ARO-APOC3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>sterile normal saline (0.9% NaCl)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fasting TG ≥ 10 mmol/L at screening refractory to standard lipid lowering therapy&#xD;
&#xD;
          -  Diagnosis of FCS&#xD;
&#xD;
          -  Willing to follow dietary counseling as per investigator judgement based on local&#xD;
             standard of care&#xD;
&#xD;
          -  Participants of childbearing potential (males &amp; females) must use highly-effective&#xD;
             contraception during the study and for at least 24 weeks following the last dose of&#xD;
             study medication. Males must not donate sperm during the study and for at least 24&#xD;
             weeks following the last dose of study medication&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test at Screening and&#xD;
             cannot be breastfeeding&#xD;
&#xD;
          -  Women of childbearing potential on hormonal contraceptives must be stable on the&#xD;
             medication for ≥ 2 menstrual cycles prior to Day 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use or use within the last 365 Days from Day 1 of any hepatocyte-targeted&#xD;
             siRNA or antisense oligonucleotide molecule&#xD;
&#xD;
          -  Diabetes mellitus newly diagnosed within 12 weeks of Screening or where HbA1c ≥ 9.0%&#xD;
             at Screening&#xD;
&#xD;
          -  Active pancreatitis within 12 weeks before Day 1&#xD;
&#xD;
          -  History of acute coronary syndrome event within 24 weeks of Day 1&#xD;
&#xD;
          -  History of major surgery within 12 weeks of Day 1&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Seropositive for hepatitis B virus (HBV) or hepatitis C virus (HCV)&#xD;
&#xD;
          -  New York Heart Association (NYHA) Clas II, III, or IV heart failure&#xD;
&#xD;
        Note: Additional Inclusion/Exclusion criteria may apply per protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Operations Lead</last_name>
    <phone>626-304-3400</phone>
    <email>AROAPOC@arrowheadpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type I</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

